Table 2 Baseline clinical, laboratory, and treatment related characteristic of the study participants-initiated ART in public hospitals of Jigjiga and Harar town, 2020, n = 420
Variable (n = 420) | Category | N (%) |
|---|---|---|
BMI | Mean ± S | 19.7 ± 3.6 |
Functional status | Working | 314 (74.8%) |
Ambulatory | 64 (15.20%) | |
Bedridden | 42 (10.00%) | |
Disease stage | Advanced | 210 (50.0%) |
Unadvanced | 210 (50.0%) | |
Hemoglobin | Median (IQR) | 11.5 (4.5) |
CD4 count level | Median (IQR) | 223 (258) |
OIs | Yes | 238 (56.7%) |
No | 182 (43.3%) | |
ART regimen | 1c = AZT + 3TC + NVP | 9 (2.10%) |
1d = AZT + 3TC + EFV | 3 (0.70%) | |
1e = TDF + 3TC + EFV | 381 (90.7%) | |
1f = TDF + 3TC + NVP | 14 (3.3%) | |
1j = TDF + 3TC + DTG | 13 (3.1%) | |
Medication adherence | Good | 333 (79.3%) |
Fair | 47 (11.2%) | |
Poor | 40 (9.5%) | |
HIV serostatus disclosure | Disclosed | 250 (59.5%) |
Not-disclosed | 170 (40.5%) | |
Cotrimoxazole Prophylaxis | Yes | 244 (58.1%) |
No | 176 (41.9%) |